Themelios Ventures Partners

Themelios Ventures is a life sciences investment firm founded by Dr. Mark Pruzanski, the founder and former CEO of Intercept Pharmaceuticals. The firm focuses on identifying, building, and investing in early-stage biotechnology companies with a primary emphasis on metabolic, inflammatory, and fibrotic diseases. Themelios is known for its hands-on approach, often providing strategic leadership and operational expertise to its portfolio companies. A notable success for the firm was its pivotal role in Versanis Bio, where Dr. Pruzanski served as Chairman and CEO until the company was acquired by Eli Lilly in 2023 for up to $1.9 billion. The firm leverages its deep understanding of clinical development and regulatory pathways to accelerate the growth of its investments. Headquartered in New York, Themelios Ventures continues to target high-impact therapeutic areas such as obesity and hepatology.